Cargando...
Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis
Cerivastatin, an HMG-CoA reductase inhibitor withdrawn from the market due to serious adverse effects, is metabolized primarily by CYP2C8. The occurrence of associated myotoxicity and rhabdomyolysis were attributed to altered cerivastatin pharmacokinetics due to gemfibrozil-inhibition or genetic var...
Gardado en:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2010
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2993694/ https://ncbi.nlm.nih.gov/pubmed/20739906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0b013e32833ecace |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|